NCT06286475View on ClinicalTrials.gov

A Study of VRG50635 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

March 25, 2024

Study Completion Date

April 8, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

VRG50635

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (1)

68502

Lincoln Celerion Inc.,, Lincoln

Sponsors

Lead Sponsor

Verge Genomics
All Listed Sponsors
lead

Verge Genomics

INDUSTRY

NCT06286475 - A Study of VRG50635 in Healthy Volunteers | Biotech Hunter | Biotech Hunter